Competitive Technologies, Inc. Announces Sales of Its Calmare(R) Pain Therapy Medical Device

Recent Sales Indicate Increased Interest by Physicians and Patients in New and Innovative Pain Treatments


FAIRFIELD, Conn., June 25, 2013 (GLOBE NEWSWIRE) -- Competitive Technologies, Inc. (OTCQX:CTTC) today announced two recent sales of Calmare® medical devices, one to a military hospital and one to a physician practice, both located in the Northwest region of the United States.

"These sales to such diverse sites are indicative of the interest we've seen from doctors and patients around the country and internationally," said Carl O'Connell, CTTC's President and CEO. "We are seeing the fruits of our labor in attracting medical practices for this innovative technology while we continue to seek financing for our increased Calmare sales and marketing programs."

About Competitive Technologies, Inc.

Competitive Technologies is a global leader in developing and commercializing innovative products and technologies. CTTC is multifaceted, providing distribution, patent and technology transfer, sales and licensing services.

CTTC is the licensed distributor of the non-invasive Calmare® pain therapy medical device, which incorporates the biophysical Scrambler Therapy® system developed in Italy by CTTC's client, Professor Giuseppe Marineo to treat neuropathic pain, including cancer pain. (The official Scrambler Therapy® scientific and clinical information website is at http://www.scramblertherapy.org/english.htm.) For more information on the device, visit www.calmarett.com. Visit CTTC's website: www.competitivetech.net.

Statements made about our future expectations are forward-looking statements and subject to risks and uncertainties as described in our most recent Annual Report on Form 10-K for the year ended December 31, 2012, filed with the SEC on May 31, 2013, and other filings with the SEC, and are subject to change at any time. Our actual results could differ materially from these forward-looking statements. We undertake no obligation to update publicly any forward-looking statement.


            

Tags


Kontaktdaten